The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Janssen-Cilag; Novartis; Pfizer; Pierre Fabre; Roche; Teva
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Genomic Health; Nektar; Pierre Fabre; Roche
ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).
 
Debu Tripathy
Consulting or Advisory Role - Nektar; Novartis; Pfizer; Puma Biotechnology
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Sara M. Tolaney
Research Funding - Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Andrew David Seidman
Honoraria - Eisai; Genentech; Genomic Health; Novartis
Consulting or Advisory Role - Eisai; Nektar
Speakers' Bureau - Eisai; Genentech; Genomic Health; Novartis
Research Funding - Bayer; Novartis
 
Carey K. Anders
Consulting or Advisory Role - Angiochem; Genentech/Roche; GERON; Kadmon; Lilly; Merrimack; Nektar; Novartis; Sanofi; to-BBB technologies BV
Research Funding - Angiochem (Inst); Cascadian Therapeutics (Inst); Geron (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Oncothyreon (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tesaro (Inst); to-BBB technologies BV (Inst)
Patents, Royalties, Other Intellectual Property - Jones and Bartlell; Up to Date.com
 
Nuhad K. Ibrahim
Honoraria - Roche
Travel, Accommodations, Expenses - Roche
 
Hope S. Rugo
Honoraria - Genomic Health
Speakers' Bureau - Genomic Health
Research Funding - Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Novartis; OBI Pharma; Pfizer; Roche/Genentech
 
Chris Twelves
Honoraria - Daiichi Sankyo; Eisai; Nektar
 
Veronique Dieras
Consulting or Advisory Role - Abbvie; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Volkmar Müller
No Relationships to Disclose
 
Alison Hannah
Leadership - NeoGenomics Laboratories
Stock and Other Ownership Interests - NeoGenomics Laboratories
Consulting or Advisory Role - Medivation; Nektar
Travel, Accommodations, Expenses - Medivation; Nektar
 
Mary Tagliaferri
Employment - Nektar
 
Javier Cortés
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Roche